

To: [redacted]@rivm.nl; [redacted]@rivm.nl; [redacted]@rivm.nl;
From: [redacted]
Sent: Mon 3/15/2021 7:25:09 PM
Subject: FW: DSRU Living Brief Review of Thrombosis following vaccination with COVID-19 AstraZeneca Vaccine
Received: Mon 3/15/2021 7:26:00 PM

Wellicht al bekend?

From: [redacted]@dsru.org
Sent: maandag 15 maart 2021 18:52
To: [redacted]@umcutrecht.nl
Cc: [redacted]@sciensano.be; [redacted] (Vjola) <[redacted]@umcutrecht.nl>; [redacted]@teamitresearch.com; [redacted]@idiapjgol.org; [redacted]@idiapjgol.info; [redacted]@child.pedi.unipd.it; [redacted]@clin.au.dk; [redacted]@clin.au.dk; [redacted]@u-bordeaux.fr; [redacted]@u-bordeaux.fr; [redacted]@gmail.com; [redacted]@gmail.com; [redacted]@leibniz-bips.de; [redacted]@leibniz-bips.de; [redacted]@ars.toscana.it; [redacted]@ars.toscana.it; [redacted]@sciensano.be; [redacted]@rivm.nl; [redacted]@rivm.nl; [redacted]@lareb.nl; [redacted]@lareb.nl; [redacted]@rti.org; [redacted]@rti.org; [redacted]@farmasi.uio.no; [redacted]@deplazio.it; [redacted]@deplazio.it; [redacted]@univr.it; [redacted]@univr.it; [redacted]@pentafoundation.org; [redacted]@pharmo.nl; [redacted]@pharmo.nl; [redacted]@gmail.com; [redacted] (SIMG) <[redacted]@simg.it>; [redacted]@simg.it; [redacted]@dsru.org; [redacted]@dsru.org
Subject: Re: DSRU Living Brief Review of Thrombosis following vaccination with COVID-19 AstraZeneca Vaccine

[redacted] and Colleagues

Here is our living review on thrombocytopenia and Covid-19 vaccines.

Best wishes

[redacted]

<https://www.dsru.org/pharmacovigilance-evidence-review-time-trends-in-adverse-event-reporting-in-the-eu-us-and-uk-thrombocytopenia/>

[redacted]

[redacted]

Southampton UK

www.dsru.org

DSRU Leaders in Real World Safety Studies

On 15 Mar 2021, at 15:53, [redacted] <[redacted]@umcutrecht.nl> wrote:

Dear all

Just attended a large meeting from ECDC with all regulators & NITAGs together, to assess the situation.

Currently several additional cases have been reported in many countries.


They look like heparin induced thrombocytopenia all in persons below 50 years of age all within 2 weeks after first dose,

Today the cases will be entered in Eudravigilance, which is behind now. Thursday there will be a special PRAC meeting and further communication

Would be very good if each country conducting the CEM look at their cases.

We will aim to rapidly calculate the background rates in ACCESS databases, it requires a regrouping of the coagulation disorders.

Best regards, 5.1.2e



3 - 5

Dubbel